REVIVE (Response to the Ebola Virus Vaccine)
Ebola Virus Disease
About this trial
This is an interventional prevention trial for Ebola Virus Disease focused on measuring Vaccine, Ebola, Sierra Leone, Ebola survivor
Eligibility Criteria
Inclusion Criteria: EVD survivors History of admission and discharge from an Ebola Treatment Unit as registered by the Sierra Leone Association of Ebola Survivors (SLAES). Anti-EBOV GP IgG positive by ELISA at the time of screening. ≥18 years of age. >45.5 kg (100lbs). Willingness to provide informed, written consent. Willingness to undergo all study procedures including rVSVDG-ZEBOV-GP vaccination and multiple blood collections over a period of six months. Age- and sex-matched controls Anti-EBOV GP IgG negative by ELISA at the time of screening. ≥18 years of age. Willingness to provide informed consent. Willingness to undergo all study procedures including rVSVDG-ZEBOV-GP vaccination and multiple blood collections over a period of six months. Exclusion Criteria: Have received the rVSVDG-ZEBOV-GP vaccine. Currently participating in another clinical trial involving a vaccine. Received a live vaccine within four weeks of screening. <18 years of age. Weight <45.5kg (or 100 lbs). Refusal to provide informed, written consent. Prisoners of other institutionalized individuals. Research study staff and their immediate family members. Inability to participate in research activities. Pregnant and lactating females. Known immunocompromised status. Known allergy to vaccine components.
Sites / Locations
- Kenema Government Hospital
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
Ebola Virus Disease (EVD) survivors
Community control
Participants with a history of admission and discharge from an Ebola Treatment Unit as registered by the Sierra Leone Association of Ebola Survivors (SLAES), and Anti-EBOV GP IgG positive by ELISA at the time of screening.
Age- and sex-matched controls who are Anti-EBOV GP IgG negative by ELISA at the time of screening.